KalshiBeschikbaarheid controlerenKYC vereist2% kostenGeverifieerde afwikkelingsgegevensRedelijk gekalibreerdHuidige impliciete kans
Before Oct 1, 2027 71%-15.0ptKoploper van 5 uitkomsten
Marktkwaliteit
33 / 100
Lage kwaliteit24u volume
€ 158,7
Liquiditeit
€ 179,2
Lage liquiditeitSpread
8.0 pt
Brede spreadMarktdata
Bijgewerkt 10 minuten geleden
19 aug 26, 22:001 okt 27, 3:59
Trends
0%
0%
0%
0%
Regels
If the FDA approves intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma for marketing the named outcome, then the market resolves to Yes.
Settles via:Food and Drug Administration
- An approval is defined as:
- For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
- The following constitute approvals that trigger the Payout Criterion:
- Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs
- The following do NOT constitute approvals:
Open markten
Health & Medicine
POLYMARKETHantavirus pandemic in 2026?
- No-0.3pt96%
- Yes+0.3pt4%
- Totaal volume
- € 15,3 mln.
- 24u volume
- € 14,5K
KALSHIMeasles cases in 2026?
- Above 300098%
- Above 4000+2.0pt87%
- Above 6000+4.0pt30%
+2 extra uitkomsten
- Totaal volume
- € 807,4K
POLYMARKETFDA approves skin cancer vaccine by which date?
- December 31,+1.0pt69%
- June 30,-9.0pt12%
- Totaal volume
- € 40,9K
- 24u volume
- € 1,9K
POLYMARKETHow many West Nile neuroinvasive disease cases will be reported among New York City residents in 2026?
- Fewer than 20+14.0pt39.3%
- 20 to 34+17.0pt37.4%
- 35 to 49-12.0pt14.9%
KALSHIWhich countries will report an Ebola case in 2026?
- South Sudan56%
- Burundi35%
- Rwanda30%
+13 extra uitkomsten
- Totaal volume
- € 293K
- 24u volume
- € 1,2K
POLYMARKETMeasles cases in U.S. in 2026?
- ↑500+0.1pt100%
- ↑1k+0.1pt100%
- ↑2k+0.2pt100%
+9 extra uitkomsten
- Which countries will report an Ebola disease case before October?
- Ebola pandemic in 2026?
- How many human screwworm cases will be reported in the United States in 2026?
- Heidi Overton confirmed as FDA Commissioner by which date?
- When will Heidi Overton be confirmed as Commissioner of the FDA?
- Which countries will have an Ebola case in 2026?
- When will the FDA reclassify BPC-157 to Category 1?
- FDA moves BPC-157 to Category 1 by which date?
- Hantavirus vaccine in 2026?
- What will the average number of measles cases be during Trump's term?
Veelgestelde vragen
- Wat zijn de huidige kansen voor Will the FDA approve intismeran autogene (V940/mRNA-4157)??
- Kalshi prijst Before Oct 1, 2027 op 71% per 24 augustus 2026.
- Wanneer wordt Will the FDA approve intismeran autogene (V940/mRNA-4157)? afgewikkeld?
- Will the FDA approve intismeran autogene (V940/mRNA-4157)? wordt naar verwachting op 1 oktober 2027 afgewikkeld.
- Hoe wordt Will the FDA approve intismeran autogene (V940/mRNA-4157)? afgewikkeld?
- Kalshi wikkelt deze markt als volgt af: If the FDA approves intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma for marketing the named outcome, then the market resolves to Yes.